TY - JOUR
T1 - Biomarkers for prostate cancer
AU - Makarov, Danil V.
AU - Loeb, Stacy
AU - Getzenberg, Robert H.
AU - Partin, Alan W.
PY - 2009/7/24
Y1 - 2009/7/24
N2 - The development of biomarkers for prostate cancer screening, detection, and prognostication has revolutionized the management of this disease. Prostate-specific antigen (PSA) is a useful, though not specific, biomarker for detecting prostate cancer.We review the literature on prostate cancer biomarkers, including serum markers (PAP, tPSA, fPSA, proPSA, PSAD, PSAV, PSADT, EPCA, and EPCA-2), tissue markers (AMACR, methylated GSTP1, and the TMPRSS2-ETS gene rearrangement), and a urine marker (DD3PCA3/UPM-3). Future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer.
AB - The development of biomarkers for prostate cancer screening, detection, and prognostication has revolutionized the management of this disease. Prostate-specific antigen (PSA) is a useful, though not specific, biomarker for detecting prostate cancer.We review the literature on prostate cancer biomarkers, including serum markers (PAP, tPSA, fPSA, proPSA, PSAD, PSAV, PSADT, EPCA, and EPCA-2), tissue markers (AMACR, methylated GSTP1, and the TMPRSS2-ETS gene rearrangement), and a urine marker (DD3PCA3/UPM-3). Future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer.
KW - Blood test
KW - Prostate biopsy
KW - Prostate-specific antigen (PSA)
KW - Radical prostatectomy
UR - http://www.scopus.com/inward/record.url?scp=65949096925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65949096925&partnerID=8YFLogxK
U2 - 10.1146/annurev.med.60.042307.110714
DO - 10.1146/annurev.med.60.042307.110714
M3 - Review article
C2 - 18947298
AN - SCOPUS:65949096925
SN - 0066-4219
VL - 60
SP - 139
EP - 151
JO - Annual review of medicine
JF - Annual review of medicine
ER -